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The three-dimensional structure of the papain-leupeptin complex has been determined by X-ray crystallography to a resolution of 2.1 A (overall 
R-factor = 19.8%). The structure indicates that: (I) leupeptin contacts the S subsites of the papain active site and not the S’ subsites; (ii) the ‘carbonyl’ 
carbon atom of the inhibitor is covalently bound by the Cys-25 sulphur atom of papain and is tetrahedrally coordinated; (iii) the ‘carbonyl’ oxygen 
atom of the inhibitor faces the oxyanion hole and makes hydrogen bond contacts with Gln-19 and Cys-25. 
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1. INTRODUCTION nal, free aldehyde and hydrated aldehyde, of which only 
the free aldehyde (2%) can inhibit protease activity [13]. 
Properties of the plant protease papain have been 
widely investigated since it is a typical example from the 
cysteine protease family. A variety of low molecular 
weight inhibitors of papain have been described [l-4]. 
Three dimensional structures have been reported for 
papain complexed with chloromethyl ketones [5], E-64 
[l-[N-[(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucyl]- 
amino]-4-guanidinobutane] [6] and E-64c [(+)-(2S, 3s)- 
3-( 1 -[N-(3-methylbutyl)amino]leucylcarbonyl)oxirane 
2-carboxylic acid] [7-81. 
Although peptide aldehydes have been well studied 
and are useful inhibitors of cysteine proteases, no three- 
dimensional structures of aldehydeecysteine protease 
complexes have been reported to date. The X-ray crys- 
tallographic structure of such a complex between le- 
upeptin and papain is described here. 
2. EXPERIMENTAL 
Papain is also inhibited by the peptide aldehyde 
leupeptin (Ac-Leu-Leu-Arginal) (Fig. 1) [9]. Leupeptin 
has broad specificity; it inhibits other cysteine proteases 
[4] as well as certain serine proteases (for example plas- 
min and trypsin). Leupeptin has been used to investigate 
the possible role of proteases in tumour cell invasion 
and metastasis [lo], protein synthesis [l l] and muscular 
dystrophy [ 121. 
Active papain was purified from twice-crystallized papain (Sigma) 
by mercuric-Sepharose affinity chromatography [14]. The active pa- 
pain was eluted from the column directly into an 8-fold molar excess 
of leupeptin and concentrated to 10 mg/ml. The protein was buffer 
exchanged into 10 mM phosphate buffer pH 6.3,20% methanol and 
a 4-fold molar excess of leupeptin. 
Leupeptin binds reversibly to papain. The reaction 
occurs in two steps [4]. 
E+I+EIIEI’ 
Crystals of the papainleupeptin complex were grown at 4°C m 
5510 days by the sitting drop method. The reservoir contained 500 ~1 
of Hz0 /methanol (1:2) and 60 ~1 of saturated NaCl, while the sitting 
drop contained 30.~1 of inhibited papain. Crystals of the complex were 
dissolved and assayed for caseinolytic activity in the presence of meth- 
anol (67%) and leupeptin [15]. The results confirmed that the activity 
of the crystals was 100% inhibited when compared with native papain 
assayed in the presence of methanol. 
X-ray diffraction data were collected from the crystals on a Siemens 
The inhibitor I binds non-covalently to the active site 
of the enzyme E and forms the Michaelis complex EL 
In the second step the active-site nucleophile of the 
protease attacks the aldehyde carbon atom of the bound 
inhibitor to form a hemithioacetal structure EI’. This 
complex represents a transition state analogue. It is 
tight binding with a Kd = 10e9 M for the binding of 
leupeptin to papain [13]. In solution leupeptin exists as 
an equilibrium between three species: cyclic hemiami- 
Correspondence address: C. Crawford, Universrty of Oxford, Labora- 
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Parks Road, Oxford, OX1 3QU. UK. Fax: (44) (865) 510454. Fig. 1. Chemical structure of leupeptin (taken from [12]) 
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area detector with monochromat~ Cu-Ka X-ray radiation. The crys- 
tals were orthorhombic and belonged to space group P2,2,2,. The unit 
cell parameters were : a = 44.92 A, b = 104.96 A, c = 50.97 A. The 
crystals were isomorphous with the 1.65 8, papain structure present 
in the Brookhaven data bank (reference 9pap) [16]. The diffraction 
data gave a total of 12452 unique reflections to 2.1 A (88% complete) 
of which 11026 had F, 2 2~7 (I$ The merging R-factor for the inten- 
sities over all data was 9.4%. The structure factors were phased using 
the atomic coordinates of native papain. A model of papain was fitted 
into the electron density and had an unrefined R-factor of 34.4%. The 
model was refined using the XPLOR package [17]. A (2F,-F,) exp”’ 
difference map was calculated and showed the presence of a ‘tube’ of 
electron density lying within the active site groove (Fig. 2). 
A model of the leupeptin molecule was fitted into the electron 
density using FRODO [lS] on an Evans and Sutherland ES’-10 
graphics workstation and refined. The difference map clearly indi- 
cated that the ‘carbonyl’ oxygen atom of the molecule was facing into 
the ‘oxyanion hole’ [4] (Fig. 3). The ‘carbonyl’ carbon atom was 
tetrahedral (angles set to 109.Y’ with force constants 45-50 kcaU 
molrad-*) and covalently bound to the sulphur atom of Cys-25 (bond 
length set to 1.81 A). 
A total of 211 bound solvent molecules (water and meth~ol) were 
added to the model structure. The solvent molecules in the vicinity of 
Fig. 2 A (2F,-F,)expiczc difference map (contoured at 0.260 e/A3) 
calculated for the initial, partly refined model (R=26%), as seen from 
‘within’ the active site cIeft. This model did not assume the presence 
of an inhibitor molecule bound to the papain. The positions of the 
Cys-25 sulphur atom and of the His-159 and Tyr-67 residues are 
indicated with respect o the difference electron density. 
the active site were refitted. The complex was then further refined over 
all data between 2OA and 2.1 A and a correction for the bulk solvent 
scattering was included. The final model has a residual of 19.8% over 
all data (Fig. 4). 
3. RESULTS 
The refined model indicates that the inhibitor mole- 
cule is bound within the active site by a combination of 
hydrogen bonds and hydrophobic interactions (Table I, 
Fig. 4). 
The rms deviation for all bond lengths from ideal 
stereochemistry was 0.013 A, while the angles exhibited 
an rms deviation of 2.33”. The structure showed that 
the aldehyde had reacted to form a tetrahedral 
hemithioacetal, with the oxygen atom facing the papain 
oxyanion hole. Leupeptin reacted stereospecifically, 
giving an ‘S’ stereoisomer [191. The angles about the 
asy~etric ‘carbonyl’ carbon atom in the refined struc- 
ture fell within the range 91.3” to 117”. The sulphur- 
carbon bond length refined to 1.65 A, which is shorter 
than the 1.81 A imposed as the restraint. The distance 
between the N&l atom of His- 159 and the sulphur atom 
of Cys-25 is 3.79 A, compared to 3.65 A in the native 
structure. The proton attached to the ‘carbonyl’ carbon 
atom is in the same plane as the imadazolium group of 
His-159. The imadazolium is therefore in the correct 
orientation for the NJ1 atom to donate a proton to a 
potential leaving group [5]. 
The papain subsites contacted are the S subsites as 
opposed to the S’ subsites [20] and this is consistent with 
the binding observed in the crystal structures of papain 
with other inhibitors [5-8,211. The SZ subsite within the 
papain active site has been identified as the hydrophobic 
pocket enclosed by the side-chains of Tyr-67, Pro-68, 
Phe-207, Val- 133 and Val-I 57. The leucyl group at posi- 
tion P, of the inhibitor is observed to bind within the SZ 
subsite while the leucyl group at position P, is likely to 
be involved in hydrophobic interactions with Tyr-61 
and Tyr-67 at the edge of the pocket. The backbone of 
the leucine at the P2 position of the inhibitor forms a one 
residue stretch of antiparallel b-sheet with Gly-66. The 
arginine side chain at the PI position makes hydrogen 
bonds with three waters and with one methanol mole- 
cule. Two of the same water molecules mediate indirect 
hydrogen bonds between the 4-guanidinobutane head 
group of the arginine side-chain and the backbone car- 
bony1 groups of Val-157 and Asn-64. In addition it is 
likely that the methyl groups of two methanols form 
hydrophobic contacts with the arginine side-chain at the 
C/I and Cy positions. 
Comparison of the enzyme structure in the leupeptin 
complex with the native papain structure indicated that 
the binding of leupeptin has induced only minor adjust- 
ments in the conformation of the active site. The ring 
structure of Tyr-61 has twisted away from the inhibitor 
presumably in order to accommodate the leucyl group 
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Fig. 3. A stereopair showing the (ZF,-F,)exp’” difference map (contoured at 0.300 e/A3) calculated from the fully refined model and highlighting 
the tetrahedral coordination centred upon the asymmetric carbon atom. The leupeptin molecule is Indicated in heavy outline with respect to the 
papain active site. The dotted lines indicate hydrogen bonds (less than 3.5 A). 
at the P, position of the inhibitor. The C-Ca bond has 
rotated by 1 l“, the Ca-C/3 bond by 23” and the C/?-Q 
bond by 41”. At the opposite end of the active site cleft, 
the C/3-Cy bond of the Asn-64 residue has rotated by 
24”. 
4. DISCUSSION 
A variety of intermediates are generated when papain 
reacts with substrate or an inhibitor, and the reaction 
pathway has been widely described [22-261 and re- 
Fig. 4. Stereoparr showing the leupeptin molecule bound within the papain active site. The inhrbitor is shaded dark and the papam residues it contacts 
are indicated. Bound waters are represented as filled spheres and bound methanols as filled ‘dumb-bells’. Hydrogen bonds are represented as dashed 
lines. The view is looking into the active site. 
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Table I _ 
Summary of the papain-leupeptin i teractions. See text for a description of the interactions with the bound solvent molecules 
Type of Leupeptin 
Interaction residue 
Leupeptin 
atom 
Papain residue 
contacted 
Papain atom 
contacted 
Bond 
Length (A) 
Hydrogen bonds 
(’ 3.5 A) Pl (Arg) Oxyanion Gln-19 Amide nitrogen of 
sidechain 
2.9 
PI 6%) Oxyanion cys-25 Amide nitrogen of 
backbone 
3.0 
P1 (Arg) Amide nitrogen of 
backbone 
Asp-158 Carbonyl oxygen of 
backbone 
2.9 
P2 (Leu) Carbonyl oxygen of 
backbone 
Gly-66 Amide nitrogen of 
backbone 
2.9 
P2 (Leu) Amide nitrogen of 
backbone 
Gly-66 Carbonyl oxygen of 
backbone 
3.1 
Hydrophobic contacts 
(3.5-5.0 A) P2 (Leu) 
P2 (Leu) 
P2 (Leu) 
P2 (Leu) 
P3 (Leu) 
P3 (Leu) 
Tyr-67 
Pro-68 
Val-133 
Val-157 
Tyr-6 1 
Tyr-67 
> 4.5 
> 3.9 
> 3.8 
> 4.7 
> 3.8 
> 3.6 
viewed [3,27]. The reaction of papain with an aldehyde 
inhibitor has long been assumed to generate a ‘dead- 
end’ tetrahedral structure, analogous to the transient 
thiolester transition state observed during the catalysis 
of substrate by papain. Bendall et al. [25] using ‘H 
NMR were the first to provide evidence for the presence 
of a proton attached to a tetrahedral carbon atom. Ev- 
idence for a tetrahedral complex was also given by 
Mackenzie et al. [19] who applied 13C NMR spectros- 
copy to papain complexed with iv-acetyl-D- and N-ace- 
tyl-r_-phenylalanyl[ 1 -‘3C]glycinal. There has been some 
controversy concerning the orientation of the atoms in 
the tetrahedral complex, specifically, whether or not the 
oxygen is facing the oxyanion hole. Mackenzie et al. [ 191 
postulated from their 13C NMR data that the oxygen 
atom pointed away from the oxyanion hole. Menard et 
al. [22] have suggested that stabilisation of the oxygen 
atom by Gln- 19 in the oxyanion hole is important in the 
catalysis of substrates, but not in the reaction of papain 
with an aldehyde inhibitor. Others have suggested that 
stabilisation of the transition state by the oxyanion hole 
is not even essential for the hydrolysis of substrate by 
papain [28-291 (reviewed in [3,27]). Drenth has con- 
structed a model for a tetrahedral intermediate by mod- 
ifying the structure derived from papain inhibited with 
chloromethyl ketone [5]. In contrast to the data dis- 
cussed above, this adduct showed the oxygen atom to 
be stabilized in the oxyanion hole by two hydrogen 
bonds donated by the backbone amide nitrogen of Cys- 
25 and by the sidechain amide nitrogen of Gln-19. 
The structure described in this paper clearly indicates 
that the reaction of papain with leupeptin under the 
crystallization conditions described generates a single 
tetrahedral structure in which the oxygen atom sits 
within the oxyanion hole (Fig. 3). We have found the 
same backbone donor groups described by Drenth et al. 
[5] to be positioned sufficiently close to interact with the 
‘carbonyl’ oxygen atom in the papain-leupeptin com- 
plex. This therefore lends support to the interpretation 
of our structure as a tetrahedral adduct. Frankfater et 
al. [30] proposed a three-step athway for the inhibition 
of papain by an aldehyde inhibitor in which two tetrahe- 
dral adducts are generated in succession. In the first 
adduct the oxygen is in the oxyanion hole, whereas in 
the second it is not. The structure described here is 
analogous to the first adduct they describe. It is possible 
that the high concentration of methanol from which the 
complex was crystallized may have selected in favour of 
the orientation of the tetrahedral adduct observed. 
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